Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > David M. Stout Joins NanoBio Corporation's Board of Directors

Abstract:
NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the appointment of David M. Stout to its Board of Directors. Mr. Stout most recently served as President of Pharmaceutical Operations for GlaxoSmithKline Pharmaceuticals.

David M. Stout Joins NanoBio Corporation's Board of Directors

ANN ARBOR, MI | Posted on May 29th, 2008

"We are pleased to welcome David to our Board of Directors and look forward to benefiting from his guidance and contributions," said James R. Baker Jr., M.D., chairman of NanoBio Corporation. "David's 30-plus years of experience in all facets of the pharmaceutical industry -- including his recent experience as head of global pharmaceutical operations for GSK, a world leader in infectious diseases -- will be invaluable to NanoBio as we approach the commercialization of our lead anti-infective and vaccine product candidates."

NanoBio's lead products are topical lotions and mucosal vaccines to combat a wide array of viruses, bacteria and fungi. They include topical treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and bacterial skin infections (including MRSA), as well as mucosal vaccines for seasonal and pandemic influenza, hepatitis B and RSV. The company's nanoemulsion-based products have demonstrated potent antimicrobial effects in several clinical trials, without safety concerns or systemic absorption. The products use a physical mode of action rather than chemical synthesis to disrupt pathogen membranes, rendering the emergence of drug resistance unlikely.

"The platform technology upon which NanoBio's products are based represents a truly novel approach to combating infections and provides a rich pipeline of anti-infective products and vaccines for the future," Stout said. "Given the company's recent and very compelling clinical results, I am particularly excited to be joining the company's board at this time. I look forward to working with NanoBio's management in bringing these new therapies and vaccines to the market."

In his most recent position as President of Pharmaceutical Operations at GSK, Mr. Stout led all global commercial activities, global manufacturing and all vaccine-related activities, including research and development, as well as other executive functions. Additionally, Mr. Stout directed the corporate pandemic flu preparedness program, an international effort that supports governments, health authorities and company employees around the world in planning to respond to a global influenza pandemic. Prior to his tenure at GSK, Mr. Stout held executive leadership positions at Glaxo Wellcome, SmithKline Beecham and Schering-Plough Corporation.

####

About NanoBio(R) Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

Contacts:
John Coffey
Vice President
Business Development
NanoBioCorporation
+1-734-302-9107

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Unveiling the quantum necklace: Researchers simulate quantum necklace-like structures in superfluids May 26th, 2017

Researchers find new way to control light with electric fields May 25th, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

Announcements

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Unveiling the quantum necklace: Researchers simulate quantum necklace-like structures in superfluids May 26th, 2017

Researchers find new way to control light with electric fields May 25th, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project